None

Almac Sciences: Company Activity and Sharing Risks in Collaborations

In this episode of PharmaTelevision News Review, Fintan Walton talks with Denis Geffroy, Vice President Business Development at Almac Sciences at Almac. Filmed at BioTrinity 2010 in Newbury, UK, they...

Charlie Morris appointed to Almac’s executive team

The Almac Group’s Clinical Technologies business unit announces that Charlie Morris has joined the company as Vice President of New Products and Services.  In this role, Mr. Morris will report dire...

Almac opens new non-GMP plant and says 'send us your CV!'

Almac Group says high demand for potent tabs and liquids was driving forces in creation of its new $10.5 million facilities.

Almac teams with DSM on biocatalysis and ramps up API capacity

Demand for larger-scale, sustainable API manufacturing capacity is a key strategy driver for Almac if developments this week are an indication.

Almac secures new discovery programme with UCL

BBRSC programme combines chemistry and biochemical engineering at UCL with Almac s biocatalysis group

BioFocus and Almac to offer fluorescent lifetime assays

Collaboration will provide BioFocus customers with compound screening and profiling services using Almac s Flexyte FLT assays

Under The Almac Umbrella: Almac replicates its success in Ireland with a full range of services in the United States

Vacation. We all look forward to it. A week or so away from the office to decompress and reduce stress – sounds great doesn't it? The vacation industry caters to those of us who want a stress-free v...

Almac, VTU Technology Form Protein Pact

Platform combines Pichia technology with Almac’s protein engineering expertise

9-Aminoacridine peptide derivatives as versatile reporter systems for use in fluorescence lifetime assays.

A novel long lifetime fluorescence reporter based on 9-aminoacridine was designed, the lifetime of which can be modulated in a defined manner when in proximity to a tryptophan residue enabling fluores...

Design and Synthesis of Conformationally Constrained Cyclophilin Inhibitors Showing a Cyclosporin-A Phenotype in C. elegans.

Cyclophilin A (CypA) is a member of the immunophilin family of proteins and receptor for the immunosuppressant drug cyclosporin A (CsA). Here we describe the design and synthesis of a new class of sma...